Compounded tirzepatide formulation challenges — looking for input

kate.chem said:

If you are going to change something, change one thing and give it long enough to express itself.

This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.

From the other side of the consultation, briefly. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

TrialTracker_MD said:

There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Coming at TrialTracker_MD’s question from a different direction. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Ask again with the specifics and you will get a better answer than this one.

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.